11/03/2026
Imagine fixing a leaking heart valve through a small incision instead of major surgery.
That’s now possible for more patients thanks to FDA approval of Edwards Lifesciences’ PASCAL Precision system for tricuspid valve repair. Severe tricuspid regurgitation can leave people exhausted, swollen, and limited—even with medication. This catheter-based option is designed to grasp and bring the valve leaflets together, aiming to improve quality of life and function for those at elevated surgical risk.
Edwards is now the only company with both repair and replacement therapies for mitral and tricuspid valves in the U.S.
What does this mean for patients who previously had limited interventional choices?
Click to learn more about the new treatment pathway.
On October 21, 2026, Edwards Lifesciences announced that the U.S. Food and Drug Administration had approved its PASCAL Precision system for transcatheter...